September 16, 2021 11:07 AM EDT
Manufacturing

Re­call re­port: Chil­dren's au­to-im­mune dis­ease drug con­t­a­m­i­nat­ed with mold and yeast

Josh Sullivan

A drug used to treat an au­to-im­mune dis­ease in chil­dren has been vol­un­tar­i­ly re­called by drug­mak­er Ja­cobus Phar­ma­ceu­ti­cal af­ter re­ports of the tablets be­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times